News >

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Apr 16, 2019

Gilles A. Salles, MD, PhD

Gilles A. Salles, MD, PhD
Daratumumab (Darzalex) was associated with low overall response rates (ORRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma (MCL), missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication